Breast Cancer

William J. Gradishar, MD, discusses the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and stable brain metastases.

Ann H. Partridge, MD, MPH, discusses the role of genomic testing in breast cancer.

The FDA has provided an update on breast implant-associated adverse effects, such as breast implant-associated anaplastic large cell lymphoma and breast implant illness.

Tesetaxel in combination with a reduced dose of capecitabine led to a significant improvement in progression-free survival versus the approved dose of capecitabine alone, meeting the primary end point of the phase 3 CONTESSA trial.

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the role of extended adjuvant endocrine receptor–positive breast cancer.

In our exclusive interview, Dr. Meisel and Dr. Hamilton provided insight on key data from the 2020 ASCO Virtual Scientific Program and best practices in managing patients during the coronavirus disease 2019 pandemic.

Experts share insight on their clinical experience with interstitial lung disease.

Recently developed treatments for HER2-positive breast cancer, lung cancers, and gastrointestinal cancers include antibody-drug conjugates, CDK4/6 inhibitors, and immuno-oncology agents.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​the utility of sacituzumab govitecan-hzi​y in metastatic triple-negative breast cancer.

Denise Yardley, MD, discusses challenges with ​resistance mechanisms in hormone receptor–positive, HER2-negative breast cancer. 

Debu Tripathy, MD, discusses tucatinib and fam-trastuzumab deruxtecan-nxki as 2 exciting drug approvals in the constantly changing HER2-positive breast cancer treatment paradigm.

A new, recently patented liquid biopsy device designed to detect small amounts of genetic and cellular material from tumors in the bloodstream of patients with early-stage, recurrent triple negative breast cancer, following neoadjuvant chemotherapy, has shown great accuracy and sensitivity.

Erika P. Hamilton, MD, discusses updated data from the phase 2 HER2CLIMB trial examining tucatinib in patients with HER2-positive breast cancer and brain metastases.

Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.

Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Denise Yardley, MD, discusses the role of endocrine therapy in combination with CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.

In our exclusive interview, Dr. Pegram discusses the unique structure of trastuzumab deruxtecan, initial and subset analyses from the DESTINY-Breast01 trial, potential adverse effects, and recommended management strategies for the agent.

Novel antibody-drug conjugates introduce promising options for the management of patients with HER2-positive breast cancer; however, management of drug-related toxicities and optimal sequencing of HER2-targeted therapies remains an ongoing challenge.

Ruth O’Regan, MD, discusses emerging CDK4/6 inhibitor combinations in breast cancer.

Ado-trastuzumab emtansine demonstrated a consistent invasive disease-free survival benefit versus trastuzumab in patients with HER2-positive breast cancer across all biomarker subgroups evaluated in the pivotal phase 3 KATHERINE trial.

Heather ​S. Han, MD, discusses the importance of pathologic complete response in breast cancer.